REVELATION BIOSCIENCES, INC. Repayments of Convertible Debt
REVELATION BIOSCIENCES, INC. (REVB) reported Repayments of Convertible Debt of $0 for the 12-month period ending 2023-12-31, per its 10-K/A filed 2024-09-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2024-09-23
- REVELATION BIOSCIENCES, INC. repayments of convertible debt for the quarter ending 2023-12-31 was $0.00.
- REVELATION BIOSCIENCES, INC. repayments of convertible debt for the quarter ending 2023-09-30 was $0.00.
- REVELATION BIOSCIENCES, INC. repayments of convertible debt for the quarter ending 2023-06-30 was $0.00.
- REVELATION BIOSCIENCES, INC. repayments of convertible debt for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- REVELATION BIOSCIENCES, INC. repayments of convertible debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- REVELATION BIOSCIENCES, INC. repayments of convertible debt for fiscal 2022 was $2.50M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-23 | $0.00 derived: sum of 2 quarters · filed 2024-09-23 | $0.00 derived: sum of 3 quarters · filed 2024-09-23 | $0.00 10-K/A · filed 2024-09-23 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-09-23 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $0.00 derived: sum of 3 quarters · filed 2024-09-23 | $0.00 derived: sum of 4 quarters · filed 2024-09-23 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-22 | $0.00 derived: sum of 2 quarters · filed 2024-09-23 | $0.00 derived: sum of 3 quarters · filed 2024-09-23 | $0.00 derived: sum of 4 quarters · filed 2024-09-23 |
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-23 | $0.00 derived: sum of 2 quarters · filed 2024-09-23 | $0.00 derived: sum of 3 quarters · filed 2024-09-23 | $2.50M 10-K/A · filed 2024-09-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $2.50M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $2.50M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $2.50M 10-Q · filed 2023-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |